OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Letters is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
NSUN2-mediated m5C modification of KDM6B mRNA enhances osteoclast differentiation and promotes breast cancer bone metastasis	337
LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation	311
METTL3 regulates M6A methylation-modified EBV-pri-miR-BART3-3p to promote NK/T cell lymphoma growth	185
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance	167
Nervous system in colorectal cancer	165
An emerging aspect of cancer neuroscience: A literature review on chemotherapy-induced peripheral neuropathy	147
A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research	146
Corrigendum to “Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations” [619 1 (2025) 217668 1–13]	126
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove data	119
CD155 in tumor progression and targeted therapy	116
CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia	115
Tumor-targeted exosomes for delivery of anticancer drugs	114
KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA	109
Valproate and lithium: Old drugs for new pharmacological approaches in brain tumors?	108
Targeted inhibition of the expression of both MCM5 and MCM7 by miRNA-214 impedes DNA replication and tumorigenesis in hepatocellular carcinoma cells	103
PROTACs: Novel tools for improving immunotherapy in cancer	103
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance	103
Fatty acids in cancer chemoresistance	103
PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma	103
Integrated analysis of ascites and plasma extracellular vesicles identifies a miRNA-based diagnostic signature in ovarian cancer	102
TIM3 on natural killer cells regulates antibody-dependent cellular cytotoxicity in HER2-positive gastric cancer	99
Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells	98
Evaluation and preservation of fertility in patients with hematologic malignancies	97
Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects	97
Regulation of gut microbiota on immune cell ferroptosis: A novel insight for immunotherapy against tumor	93

The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes	92
Editorial Board	89
Hypoxia effects on glioblastoma progression through YAP/TAZ pathway regulation	89
M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1	87
ASPH dysregulates cell death and induces chemoresistance in hepatocellular carcinoma	84
A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma	82
Hormonal and neuronal interactions shaping the brain metastatic microenvironment	82
Sialic Acids: Sweet modulators fueling cancer cells and domesticating the tumor microenvironment	82
Versatility of Exosomes for Cancer Therapy	81
Bypassing the Tollway; a novel path to TLR4 independent stemness regulation	80
IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma	80
Coiled-coil domain-containing 154 promotes colorectal cancer proliferation and metastasis via interacting with minichromosome maintenance complex component 2	78
Ethnic Diversity and Metabolic Variations in Ovarian Cancer Cells: Implications for Personalized Medicine Strategies	77
Understanding the significance of biological clock and its impact on cancer incidence	77
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds	77
Editorial Board	76
Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth	74
Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective	74
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy	72
The E3 ligase TRIM22 functions as a tumor suppressor in breast cancer by targeting CCS for proteasomal degradation to inhibit STAT3 signaling	71
Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching	70
Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy	70
FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity	70
MDSCs in bone metastasis: Mechanisms and therapeutic potential	68
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy	68
Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model	68
Clinical development of immuno-oncology therapeutics	68
Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer	68
The role of Hippo/YAP1 in cancer-associated fibroblasts: Literature review and future perspectives	68
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation	67
Osteopontin promotes tumor microenvironment remodeling and therapy resistance	66
Novel role of MKRN2 in regulating tumor growth through host microenvironment and macrophage M1 to M2 switch	63
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer	63
Corrigendum to “Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells” [Cancer. Lett. (382) 2016-11-28; 382(2):215–230]	63
Unscheduled polyploidy synergizes with oncogenic mutations to enhance genome instability and tumorigenesis	63
Proteomics and single cell profiling identify keratin driven preexisting immunity influences lung squamous carcinoma neoadjuvant therapy	62
Tuning cellular metabolism for cancer virotherapy	61
Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model	61